Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide  that was being developed for inflammatory bowel diseases (IBD). ... Read more

Stock Quote

PTGX (Common Stock)
$6.92 + 0.03 (0.44%)
Exchange :NASDAQ
Volume :70,474
Today's Open$6.89
Previous Close$6.89
Data as of December 17, 2018 2:46 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $6.92 with a 52 week high of $23.97 and a 52 week low of $5.49.

Recent Press Releases

December 13, 2018

Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943 read more

December 05, 2018

Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference read more

November 27, 2018

Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease read more

Upcoming Events

There are currently no events scheduled.


Download Documentation Investor Presentation
Data provided by Nasdaq. Minimum 15 minutes delayed.